A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). (NCT01021423), a randomized phase 3 study. The primary outcome is Progression-free Survival (PFS).

2. Clinical Question

3. Trial Design

This was a phase 3, randomized, parallel-group study with a placebo control. It was described as multicenter, double-blind, and quadruple-masked. Participants were intended to receive lenalidomide or an identical matched placebo as maintenance after completing first-line combination chemotherapy. The study population was patients with mantle cell lymphoma who were not transplant candidates and had achieved a partial response or complete response.

The lenalidomide regimen was 15 mg orally once daily on Days 1–21 of each 28-day cycle. Placebo followed the same schedule. Treatment could continue for a maximum of 2 years, or until disease progression, unacceptable toxicity, or voluntary withdrawal. The registry lists enrollment as 9 and the study status as terminated.

The record gives a study start date of 2010-04-01 and a primary completion date of 2011-03-01. It states that the sponsor prematurely terminated the trial after new unpublished data made the current design no longer clinically relevant; specifically, a control arm with no active treatment was no longer considered appropriate. The sponsor stated that termination was not based on safety concerns.

These features describe the planned comparison and the registry’s account of termination. They do not establish that the comparison was completed or that treatment exposure followed the intended schedule. The record does not report detailed allocation procedures, adherence, participant flow, or treatment discontinuations.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Randomization was stratified according to 1) the type of first-line induction chemotherapy (anthracycline-based, fludarabine-based, or rituximab-bendamustine combination therapy) and 2) the response to first-line induction chemotherapy (complete response or partial response).

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Study terminated prematurely. Analysis not performed.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Progression-free Survival (PFS), measured over up to 7 years.

The primary endpoint was progression-free survival (PFS), with a timeframe of up to 7 years. The registry defined it as the time from randomization to the first observation of disease progression or death due to any cause. Progression was defined using the 2007 Revised Response Criteria for Malignant Lymphoma: a new lesion or an increase by 50% of previously involved sites from nadir.

In general, a time-to-event endpoint uses both whether an event occurred and how long participants remained event-free. Including death from any cause in this definition means that death counts as an event even if disease progression has not first been recorded. Such endpoints can be useful when the timing of progression or death is central to the research question and follow-up may vary between participants.

The registry states that the study was terminated prematurely and the PFS analysis was not conducted. It also says that the analysis was not performed in the primary outcome population description. No group-specific PFS estimates, event counts, confidence intervals, or statistical test results are reported in the registry record. Consequently, the endpoint definition describes what the study intended to measure, not an observed treatment comparison.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a randomized, parallel-group design with placebo control and quadruple masking. Randomization is intended to make treatment assignment independent of measured and unmeasured participant characteristics on average. Masking is intended to reduce the influence of treatment knowledge on care, participant reporting, and outcome assessment. These are general design principles; the registry record does not describe the specific randomization procedure or identify the roles covered by its masking label.

What would a PFS comparison estimate?

In general, a PFS analysis compares the time from randomization until progression or death between study groups. Because participants may have different follow-up times, time-to-event methods can account for participants who have not experienced an event by the time their available follow-up ends. Such participants are commonly treated as censored at their last known event-free time. Censoring requires assumptions about the relation between loss of observation and event risk; the registry record does not report censoring details or the methods used to address it.

The record defines progression using the 2007 Revised Response Criteria for Malignant Lymphoma and includes death from any cause as a PFS event. However, it reports no PFS analysis. The statistical method intended for comparing PFS, the handling of censoring, and any assumptions about proportional hazards are not reported in the registry record.

How should uncertainty be understood?

In general, an estimate describes the observed treatment contrast, while a confidence interval describes the range of values reasonably compatible with the data under the statistical model. A narrow interval indicates greater precision than a wide interval. A p-value addresses how compatible the observed data are with a specified null hypothesis under model assumptions; it is not a measure of the probability that a treatment works. No PFS estimate, confidence interval, or p-value is reported for this study, so these concepts cannot be applied to a trial-specific efficacy result.

In general, statistical significance and clinical importance are different questions. A result can be statistically distinguishable from a null value without necessarily being important to patients, while a potentially important estimate can remain uncertain when data are limited. Here, the registry provides no primary endpoint estimate to assess for either statistical significance or clinical importance.

Why do group sizes and event counts matter?

In general, the amount of information in a trial depends on the number of participants observed, the number and timing of outcome events, and the completeness and duration of follow-up. For a time-to-event outcome, the event information is especially important. A participant count alone cannot show how many PFS events occurred or how precisely a treatment contrast could be estimated. The registry lists enrollment as 9 but does not report PFS event counts or follow-up details.

Over-dispersion is a general issue for count outcomes when variability exceeds what a simple count model would expect. If present, it can make conventional standard errors too small and confidence intervals too narrow unless the analysis accounts for the extra variability. The registry record does not report an analysis of this kind, and this issue does not provide a way to recover the missing PFS comparison.

What do planning illustrations mean?

In general, sample-size planning illustrations show how many participants might be needed under specified assumptions about an effect, significance level, allocation, and statistical method. They are planning scenarios, not observed results and not evidence that a trial had a particular probability of detecting an effect. The registry notes that the illustrations use the observed effect and specify a two-sided significance level of 0.05, equal allocation, and a normal approximation. For time-to-event illustrations, the stated quantity is the total number of events; for other illustrations, it is participants per arm.

Those assumptions are described as a planning illustration, not as the study’s own design justification. The registry record does not report a sample-size justification for the trial. Since the primary PFS analysis was not conducted, the record also does not provide a PFS effect estimate that can be interpreted as an observed treatment effect. The planning assumptions should not be read as observed power or as a replacement for trial results.

What is missing from the analysis record?

The registry reports zero analyses. It does not report the statistical model, analysis population, treatment-effect estimate, adjustment variables, missing-data methods, or sensitivity analyses. Nor does it report whether any interim analysis was planned or performed. These omissions limit statistical interpretation: a randomized design alone does not reveal the result of the comparison, and an endpoint definition alone does not specify how the endpoint was analyzed.

10. Multiplicity, Missing Data and Analysis Populations

Multiplicity arises when a study conducts several statistical tests or evaluates several outcomes, because the chance of obtaining at least one apparently unusual result can increase as testing expands. In general, a statistical plan may define a primary outcome, specify the order of testing, or adjust significance thresholds to address this issue. The registry record does not report a multiplicity strategy, any testing hierarchy, or an adjustment method.

The registry identifies PFS as the primary outcome and lists secondary outcomes including overall survival, participants with treatment-emergent adverse events, time to progression, time to treatment failure, and participants with a tumor response. It reports six outcome measures, but gives no analyses. Since the primary analysis was not conducted and no secondary analyses are reported, there is no set of inferential results from which to assess multiplicity or distinguish confirmatory from exploratory findings.

Missing-data handling is also not reported in the registry record. It does not describe missing endpoint assessments, censoring patterns, reasons for incomplete follow-up, or any imputation or sensitivity methods. For a time-to-event endpoint, censoring is part of the analysis, but the details and assumptions used for this trial are not reported.

The analysis populations are not described. The record does not state whether an intention-to-treat, per-protocol, or other population was used, and the primary outcome description says the analysis was not performed. The design and enrollment information cannot establish which participants would have been included in an efficacy analysis. These gaps preclude assessment of how missing observations, analysis-population choices, or multiple outcomes might have affected a treatment estimate.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: squamous cell carcinoma (25.0%).

The registry reports serious adverse-event figures for the two groups. In the lenalidomide group, 4 participants were at risk and 1 was affected by a serious adverse event. In the placebo group, 5 participants were at risk and 0 were affected by a serious adverse event. The registry lists squamous cell carcinoma at 25.0% among the top serious terms. It does not identify the group associated with that term in the listed summary, so the term should not be assigned to a group from this information alone.

For other adverse events, the registry reports 4 at risk and 4 affected in the lenalidomide group, and 5 at risk and 4 affected in the placebo group. These are counts as recorded, not adjusted comparisons. The record does not report event-specific detail for these other events in the information presented, nor does it report deaths.

In general, adverse-event counts describe events observed during a specified period and do not, by themselves, show that treatment caused an event. Interpretation depends on definitions, timing, exposure, severity, follow-up, and the completeness of reporting. With the limited counts and no reported inferential safety analysis, these figures do not establish a comparative safety effect. The sponsor stated that termination was not based on safety concerns.

12. What the Result Does, and Does Not, Mean

The registry record establishes that a phase 3 randomized study was designed to compare lenalidomide maintenance with placebo after first-line combination chemotherapy in patients with mantle cell lymphoma who were not candidates for transplantation and had achieved a partial response or complete response. It also records the planned regimen, the PFS definition, enrollment of 9, and termination of the study.

It does not establish whether lenalidomide prolonged PFS, shortened PFS, or had no effect on PFS in this trial. The primary analysis was not conducted, and no efficacy estimate or uncertainty interval is reported. The lack of a result must not be treated as a negative trial result or evidence that the groups were equivalent.

The sponsor’s stated reason for termination was that new unpublished data made the existing design no longer clinically relevant and that a control arm with no active treatment was no longer appropriate. The sponsor also said that termination was not based on safety concerns. This explanation concerns the decision to stop the trial; it is distinct from a result based on the trial’s own planned PFS comparison.

The adverse-event information offers limited descriptive counts but does not support a firm causal or comparative safety conclusion. The registry does not report a completed analysis of the secondary outcomes, participant-level characteristics, follow-up details, or the statistical methods that would be needed to assess those outcomes.

Accordingly, the record is informative about the trial’s question, design, intended endpoint, and termination, but it does not provide an answer to the main efficacy question. It should be interpreted as an incomplete trial record rather than as evidence for or against a treatment effect.

13. Why This Trial Matters Statistically

This trial matters statistically because it illustrates the difference between a well-defined research question and an answer supported by analyzed data. The study specified a randomized comparison, a placebo control, and a time-to-event primary endpoint. Those design features describe how the question was intended to be addressed, but they cannot supply the missing estimate when the primary analysis was not conducted.

Termination also changes what can be learned from a planned trial. The registry records an enrollment of 9, but does not report PFS events or follow-up. For time-to-event analyses, the number and timing of events are important to the information available; enrollment alone cannot show the precision of a treatment comparison. Because no primary result is reported, the registry cannot show whether the trial accumulated enough information to answer its planned question.

The stated reason for stopping is also statistically important to interpret correctly. The sponsor described new unpublished data that made the study design no longer clinically relevant and said that a no-active-treatment control was no longer appropriate. This rationale is not the same as an observed efficacy or safety finding from this trial. The record says termination was not based on safety concerns.

Finally, this record emphasizes why outcome definitions and analysis plans are not interchangeable with results. PFS is carefully defined, but the registry does not report the analysis method, effect estimate, or uncertainty. The practical statistical lesson is to distinguish a trial’s intended comparison from its completed evidence, and to treat missing results as unknown rather than as proof of no effect.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The central limitation is that the primary PFS analysis was not conducted. The registry therefore provides no treatment-effect estimate, event count, confidence interval, or p-value for the primary outcome. The study’s stated endpoint and timeframe describe the plan, not an observed result.

The registry lists enrollment as 9, but does not provide detailed information on participant characteristics, treatment exposure, adherence, follow-up duration, withdrawals, or the reasons participants may have stopped treatment. It is not possible from the record to judge representativeness, outcome completeness, or the extent of follow-up. The statistical analysis populations are not reported.

The registry reports zero analyses and does not describe the statistical plan, missing-data approach, censoring methods, multiplicity strategy, or any interim analyses. The record also does not include results for the listed secondary outcomes. These omissions limit both efficacy interpretation and evaluation of the planned statistical procedures.

The safety information is limited to the posted counts and a listed serious-event term. The record does not provide enough detail to evaluate timing, exposure, event-level patterns, or a formal comparison. The sponsor’s statement that termination was not based on safety concerns provides context but does not replace a detailed safety analysis.

Finally, the stated reason for termination refers to new unpublished data, which are not described in the registry record. The rationale can be reported as the sponsor’s explanation, but its clinical or statistical implications cannot be independently assessed from this record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). — NCT01021423.
• Registry record last updated 2019-11-19; status last verified 2019-11.
• Results first posted 2011-12-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01021423 was a phase 3, randomized, parallel-group, placebo-controlled, quadruple-masked study of lenalidomide maintenance after first-line combination chemotherapy for mantle cell lymphoma. The intended population was patients who were not candidates for transplantation and had achieved a partial response or complete response. Lenalidomide was scheduled at 15 mg orally once daily on Days 1–21 of each 28-day cycle, for a maximum of 2 years or until a stopping condition; placebo followed the same schedule.

The primary outcome was PFS, defined as time from randomization to disease progression or death from any cause, with a timeframe of up to 7 years. The registry states that the trial was terminated prematurely and that the primary analysis was not conducted. The sponsor attributed termination to new unpublished data that made the design no longer clinically relevant, and stated that it was not based on safety concerns.

The record lists enrollment as 9, reports limited adverse-event counts, and reports no analyses. It does not provide an efficacy result for the planned treatment comparison.